Skip to content
value.today
Incysus Therapeutics, Inc. logo

Incysus Therapeutics, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2018
Total raised
$35 M
1 round on record
Latest round
$35 M
May 2018
First round on record
May 2018
Today
Went public
See the company page

Incysus Therapeutics, Inc. is listed today as IN8Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Incysus Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$20 MPrivate placement after listing$10 to $50 million

Incysus Therapeutics, Inc.: Private sale, Dec 2025

Investors in this round

17 investors had bought by the notice of Dec 30, 2025: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Incysus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $40 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,207,200
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kate R. Rochlin · Executive Officer
  • Lawrence R. Lamb · Executive Officer
  • Patrick McCall · Executive Officer
  • William Ho · Executive Officer, Director
  • Alan S. Roemer · Director
  • Corinne R. Epperly · Director
  • Emily R. Fairbairn · Director
  • Jeremy R. Graff · Director
  • Luba R. Greenwood · Director
  • Peter S. Brandt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, CT, GA, IL, MA, MD, NY, OR, TN, TX

Signed by Patrick McCall, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 30, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2024$12 MPrivate placement after listing$10 to $50 million

Incysus Therapeutics, Inc.: Private sale, Oct 2024

Investors in this round

73 investors had bought by the notice of Oct 15, 2024: 73 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Incysus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$742,799
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kate R. Rochlin · Executive Officer
  • Lawrence R. Lamb · Executive Officer
  • Patrick McCall · Executive Officer
  • William Ho · Executive Officer, Director
  • Alan S. Roemer · Director
  • Corinne R. Epperly · Director
  • Emily R. Fairbairn · Director
  • Jeremy R. Graff · Director
  • Luba R. Greenwood · Director
  • Peter S. Brandt · Director
  • Travis R. Whitfill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in all US states

Remarks in the notice

  • On fees: “This does not include $65,000 of out of pocket expenses that the Issuer reimbursed Newbridge Securities Corporation.”

Signed by Patrick McCall, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 15, 2024. Read the notice at the SEC.

equity, optionsSEC
Dec 2023$14 MPrivate placement after listing$10 to $50 million

Incysus Therapeutics, Inc.: Private sale, Dec 2023

Investors in this round

20 investors had bought by the notice of Dec 28, 2023: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Incysus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$643,470
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kate R. Rochlin · Executive Officer
  • Lawrence R. Lamb · Executive Officer
  • Patrick McCall · Executive Officer
  • Trishna R. Goswami · Executive Officer
  • William Ho · Executive Officer, Director
  • Alan S. Roemer · Director
  • Corinne R. Epperly · Director
  • Emily S. Fairbairn · Director
  • Jeremy R. Graff · Director
  • Luba R. Greenwood · Director
  • Peter S. Brandt · Director
  • Travis R. Whitfill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in CA, CT, FL, IL, MD, NJ, NY, SC, TX

Remarks in the notice

  • On the amounts: “This amount does not include potential proceeds to the issuer upon exercise of warrants.”

Signed by Patrick McCall, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 28, 2023. Read the notice at the SEC.

equity, optionsSEC
May 2018$35 MNo. 1$10 to $50 million

Incysus Therapeutics, Inc.: Raise no. 1, May 2018

Investors in this round

33 investors had bought by the notice of Sep 4, 2020: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Incysus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Larry Lamb · Executive Officer
  • Melissa Beelen · Executive Officer
  • William Ho · Executive Officer, Director
  • Peter Brandt · Director
  • Thomas Cirrito · Director
  • Travis Whitfill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Ho, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Sep 4, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Incysus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: Incysus Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Incysus Therapeutics, Inc. are on record.

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Incysus Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
BIOS Advisors GP, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Capital Management, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Equity Partners III, LPPrivate equitynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Bios Equity Partners II, LPPrivate equitynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund III, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund III NT, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund III QP, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund II, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund II NT, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Fund II QP, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
BIOS Incysus Co-Invest I, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cavu Advisors, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cavu Management, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Transcend Partners Opportunity Fund LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.

Largest shareholders today

Institutions holding IN8Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Incysus Therapeutics, Inc.
NameRoleNamed in
Kate R. RochlinExecutive officerDec 2025
Lawrence R. LambExecutive officerDec 2025
Patrick McCallExecutive officerDec 2025
William HoExecutive officerDec 2025
Trishna R. GoswamiExecutive officerDec 2023
Larry LambExecutive officerSep 2020
Melissa BeelenExecutive officerSep 2020
Alan S. RoemerDirectorDec 2025
Corinne R. EpperlyDirectorDec 2025
Emily R. FairbairnDirectorDec 2025
Jeremy R. GraffDirectorDec 2025
Luba R. GreenwoodDirectorDec 2025
Peter S. BrandtDirectorDec 2025
William HoDirectorDec 2025
Travis R. WhitfillDirectorOct 2024
Emily S. FairbairnDirectorDec 2023
Peter BrandtDirectorSep 2020
Thomas CirritoDirectorSep 2020
Travis WhitfillDirectorSep 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.